University at Buffalo - The State University of New York
Skip to Content

Faculty Profiles

Julian, Ambrus, Jr.
Email: jambrus@buffalo.edu
Phone: (716) 859-2985

Specialty/Research Focus:
Allergy and Immunology; Rheumatology; Immunology; Autoimmunity

Research Summary:
My research revolves around IL-14 and its role in immunological memory. Studies delve into 3 areas - vaccination, autoimmunity and lymphoid malignancies. The majority of my current work involves studies examining early events in Sjogren‘s syndrome. We have identified new autoantibodies that occur early in the course of the disease. We are examining mediators involved in the early injury to the salivary and lacrimal glands. We are studying events that result in the transition from the autoimmune disease to lymphoma.

Sean, Brady
Brady, Sean, MDClinical Assistant Professor of Medicine
Email: spbrady@buffalo.edu
Phone: 716-961-9900

Specialty/Research Focus:
Allergy and Immunology

Research Summary:
I am specialist in the field of Allergy and Immunology. I provide care at the UBMD office in Amherst, Buffalo General Medical Center and WNY Veterans Administration Hospital. My clinical interests include allergic rhinitis, allergic conjunctivitis, sinus disease, asthma, chronic cough, drug allergy, food allergy, eosinophilic esophagitis, urticaria (hives), angioedema (swelling), atopic dermatitis, contact dermatitis, stinging insect allergy, anaphylaxis and immune system deficiencies. I have a strong interest in medical education and enjoy teaching medical students, residents and fellows.

Terry, Connell
Connell, Terry, PhDProfessor of Microbiology and Immunology, Adjunct Professor of Oral Biology
Email: connell@buffalo.edu
Phone: (716) 829-3364

Specialty/Research Focus:
Allergy and Immunology; Medical Microbiology; Infectious Disease; Microbiology; Genomics and proteomics; Immunology; Microbial Pathogenesis; Molecular and Cellular Biology; Molecular Basis of Disease; Molecular genetics; Gene Expression; Signal Transduction; Protein Function and Structure; Bacterial Pathogenesis

Research Summary:
Research efforts in my laboratory are focused in the fields of immunology and bacterial pathogenesis, two diverse fields of biomedical research for which I have two separate research groups. Projects in both fields are performed by undergraduates, doctoral and master’s degree students, postdoctoral fellows and senior research associates. One major focus of my laboratory is studying the regulation of mucosal immune responses. We investigate the cellular and molecular events by which Type II heat-labile enterotoxins (HLTs), produced by certain strains of Escherichia coli, modulate immune responses. We have demonstrated that LT-Ilia, LT-IIb and LT-IIc, when co-administered with an antigen, have the capacity to enhance antibody and cellular immune responses to that antigen. Using a variety of immunological and cellular technologies, including flow cytometry, fluorescence resonance energy transfer (FRET) detection, cytokine multiplex analysis, mutagenesis, quantitative Reverse Transcription PCR (qRT-PCR), RNA-sequencing (RNA-Seq) and a variety of transgenic mice, we are investigating the mechanisms by which these immunomodulators productively interact with various immunocompetent cells (T cells, B cells, dendritic cells, macrophages) to induce or suppress cytokine production, costimulatory ligand expression and cellular proliferation. A practical outgrowth of these experiments is the potential to engineer novel recombinant vaccines by genetically fusing antigens from different pathogens to the enterotoxins. Recent experiments have shown that these HLT are lethal for triple-negative breast cancer cells, which has opened a new area of oncological research for the lab. A second focus of my laboratory is to investigate the molecular mechanisms by which adherent-invasive Escherichia coli (AIEC) induce, exacerbate or prolong the symptoms of inflammatory bowel disease (IBD) and Crohn’s disease, two acute and chronic inflammatory diseases of the human gut. In vitro, AIEC strains invade into the cytoplasm of several epithelial cell lines. Using recombinant screening methods and RNA-Seq technologies, we are identifying the genes of AIEC that are required to attach and to invade gut cells.

Heather, Lehman
Lehman, Heather, MD, FAAAIClinical Associate Professor
Email: hkm@buffalo.edu
Phone: (716) 878-7258

Specialty/Research Focus:
Allergy and Immunology; Pediatrics

Shivani, Rasalingam
Rasalingam, Shivani, MDClinical Assistant Professor
Email: sr18@buffalo.edu
Phone: (716) 878-7258

Specialty/Research Focus:
Allergy and Immunology; Pediatrics

Mark, Sands
Sands, Mark, MDClinical Professor
Email: mfsands@buffalo.edu
Phone: (716) 859-5600

Specialty/Research Focus:
Allergy and Immunology; Pulmonary & Critical Care Medicine

Research Summary:
I am trained in Adult Pulmonary/Critical Care, as well as Allergy/Immunology. My clinical interests include Asthma, and Urticaria/Angioedema. My principal practice site is the Veterans Administration Healthcare System of Western NY as well as Buffalo General Hospital for in-patient consultation. My research interests focus primarily on asthma, lung matrix biology, particularly matrix metalloproteinases and their inhibitors, and also therapy of urticarial and angioedema

Stanley, Schwartz
Schwartz, Stanley, MD, PhDDistinguished Professor, Medicine, Pediatrics, and Microbiology & Immunology; Division Chief, Allergy-Immunology-Rheumatology
Email: sasimmun@buffalo.edu
Phone: 716-859-2260

Specialty/Research Focus:
Allergy and Immunology; Immunology; Proteins and metalloenzymes; RNA

Thomas, Tomasi
Email: tomasi@buffalo.edu
Phone: (716) 845-5770

Specialty/Research Focus:
Allergy and Immunology; Oncology

Research Summary:
-Studies in this laboratory have established that trophoblast cells have developed two novel mechanisms of silencing MHC class II genes: an upstream negative-regulatory element controlled by two trophoblast specific DNA binding proteins, and repression of transcription of the class II transactivator (CIITA). Recently, some human tumor cells have been shown to have a trophoblast phenotype, in that CIITA and class II are not inducible with g-IFN or other cytokines. In collaboration with A. Latif Kazim and Carleton Stewart, RPCI, we have shown that tumor cell lines that are not responsive to g-IFN despite an intact g-IFN receptor and Jak-Stat signaling pathway, can be induced to express mRNA and cell surface class II with agents that acetylate histones and remodel chromatin structure. Unexpectedly, we found that class II induction by inhibitors of histone deacetylase occurred in the apparent absence of transcription of CIITA. Recent studies with mutant cell lines defective in established class II regulatory genes suggest the existence of a pathway independent of CIITA, the presumed master regulator of MHC class II. During these experiments, we also showed that the expression of two other molecules of immunological importance MHC class I and CD40 also were activated by histone deace-tylase inhibitors. Dr. William Magner has joined my laboratory recently and, together with Dr. Elizabeth Repasky, we extended these studies to different mouse tumor cell lines, and demonstrated by flow analysis the induction of MHC class I and II genes as well as the costimulator molecule CD40. We are exploring the spectrum of antigens expressed on tumor cells treated with histone deacetylase inhibitors including TGF-b receptors and tumor associated antigens. We are determining whether treated tumor cells administered in vivo show enhanced immunity and decreased tumorigenicity to subsequent challenge with wild type cells. In this regard, as first shown by Ostrand-Rosenberg, et al., mouse sarcoma I cells, when transfected with MHC class II, produce solid and long-lasting immunity to inoculation with wild type cells. Thus, these findings have significance in tumor escape mechanisms and the development of vaccines. We have explored the possibility that repressors of CIITA transcription exist in trophoblast and tumor cells, thus inhibiting class II expression and its induction by g-IFN. TGF-b1 and IL-10 are produced by all of the tumor cell lines we examined that were deficient in class II expression. Since these cytokines repress class II transcription by inhibiting CIITA transcription, the possibility of autocrine inhibition is suggested. The mechanisms of TGF-b repression may involve recruitment of deacetylase enzymes to the class II promoter site by CREB-CBP-CIITA complexes. This possibility will be explored using chromatin immunoprecipitation techniques. Studies have been initiated on the role of transcriptional cofactors with histone acetyltransferase activity, as well as the role of ATP-dependent multiprotein chromatin remodeling complexes in regulating MHC gene expression. Our work also has demonstrated that TGF-b can bind to receptors on dendritic cells and inhibit antigen presentation. Moreover, serum TGF-b1 levels are elevated in AIDS and DC cells derived from the blood of HIV patients who have high levels of cell surface TGF-b1. Treatment with anti-TGF-b, or anti-type III TGF-b receptor antibodies, or the addition of GM-CSF reverses the defect in antigen presentation in AIDS-PBL in vitro. Prelimin-ary clinical studies in patients with advanced AIDS, in collaboration with the Department of Medicine, have shown that GM-CSF reverses the antigen presentation defect and significantly raises CD4 cell numbers in many, but not all, AIDS patients. To test the hypothesis frequently quoted in the literature that aberrant expression of class II antigens on fetal trophoblast cells is responsible for most spontaneous abortions, transgenic animals are being prepared that will express class II on placental trophoblast cells at a specific time during gestation. We have cloned 300 bp of the proximal promoter of a trophoblast specific gene, 4311, and placed this in an expression plasmid upstream of the full-length CIITA gene. This construct was shown to be active when transfected into freshly isolated mouse spongiotrophoblast cells. Thus, mice bearing this transgene should begin to transcribe CIITA at day 6 of gestation when the 4311 gene is first expressed. If the hypothesis is correct, then MHC class II should be expressed by day 7-8, and abortion would occur. A dominant negative of CIITA has been produced by deletion of part of the activation domain of CIITA, and this could potentially be expressed in trophoblast cells of strains with high abortion rates. If as postulated by others, fetal loss in these abortogenic strains is due to aberrant expression of CIITA and subsequently class II, the dominant negative should inhibit abortions in these mice.